Skip to main content

Additional Information about Required OnCore Fees

A line-item direct cost is an emerging standard to be incorporated into study budgets. This is part of a larger effort to better manage the financial performance of clinical trials. Fees are assessed at study start-up (site initiation visit) and annually, thereafter. The exact CTMS Fees can be found in the Clinical Research Institutional Fee Schedule-(UU SOP 13). These fees include a one-time start-up fee and annual maintenance fees throughout the life of the study and include F&A/overhead. The CTMS fee represents a fee-for-service provided by the CTSI, Clinical Research Support Office for use of the CTMS system. These fees are non-negotiable.

Study teams will receive an invoice from the Clinical Research Support Office for CTMS fees. 

It is necessary to assess a standard fee for all studies that require registration in OnCore. OnCore assesses their fees to the University of Utah based on the use of the system, not the size of the budget or type of study. 


No OnCore start-up/annual fees will be assessed if using OnCore for participant payments only. See our Participant Payments page for more information. 

Please see our About OnCore page for which studies are required to be registered in OnCore. A formal waiver process for OnCore fees is available by submitting a ticket to Service Now Support.

  • Fees are in effect now for all new studies that were added to OnCore as of 05/01/22.
  • Studies that were underway and had a fully executed budget and contract prior to 05/01/22 will not be assessed CTMS fees.

For additional questions regarding the financial implications of the OnCore CTMS system, including startup and annual fees, please submit a Service Now ticket for assistance.